CRISPR-Cas systems: ushering in the new genome editing era (original) (raw)

Abstract

In recent years there has been great progress with the implementation and utilization of Clustered Regularly Interspaced Palindromic Repeats (CRISPR) and CRISPR-associated protein (Cas) systems in the world of genetic engineering. Many forms of CRISPR-Cas9 have been developed as genome editing tools and techniques and, most recently, several non-genome editing CRISPR-Cas systems have emerged. Most of the CRISPR-Cas systems have been classified as either Class I or Class II and are further divided among several subtypes within each class. Research teams and companies are currently in dispute over patents for these CRISPR-Cas systems as numerous powerful applications are concurrently under development. This mini review summarizes the appearance of CRISPR-Cas systems with a focus on the predominant CRISPR-Cas9 system as well as the classifications and subtypes for CRISPR-Cas. Non-genome editing uses of CRISPR-Cas are also highlighted and a brief overview of the commercialization of CRISPR is provided.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (39)

  1. Ishino Y, Shinagawa H, Makino K, et al. Nucleotide sequence of the iap gene, responsible for alkaline phospha- tase isozyme conversion in Escherichia coli, and identifica- tion of the gene product. J Bacteriol. 1987;169:5429-5433.
  2. Mojica FJM, Diez-Villaseñor C, García-Martínez J, et al. Intervening sequences of regularly spaced prokar- yotic repeats derive from foreign genetic elements. J Mol Evol. 2005;60:174-182.
  3. Jansen R, Embden JDA, Gaastra W, et al. Identification of genes that are associated with DNA repeats in pro- karyotes. Mol Microbiol. 2002;43:1565-1575.
  4. Mohanraju P, Makarova KS, Zetsche B, et al. Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems. Science. 2016;353:aad5147.
  5. Jackson SA, McKenzie RE, Fagerlund RD, et al. CRISPR-Cas: adapting to change. Science. 2017;356: eaal5056.
  6. Shmakov S, Smargon A, Scott D, et al. Diversity and evolution of class 2 CRISPR-cas systems. Nat Rev Microbiol. 2017;15:169-182.
  7. Makarova KS, Wolf YI, Alkhnbashi OS, et al. An updated evolutionary classification of CRISPR-cas sys- tems. Nat Rev Microbiol. 2015;13(11):722.
  8. Hille F, Charpentier E. CRISPR-Cas: biology, mechan- isms and relevance. Philos Trans R Soc Lond B Biol Sci. 2016;371:1707.
  9. Zhang J-H, Adikaram P, Pandey M, et al. Optimization of genome editing through CRISPR-Cas9 engineering. Bioengineered. 2016;7(3):166-174.
  10. Deltcheva E, Chylinski K, Sharma CM, et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature. 2011;471(7340):602-607.
  11. Fu Y, Foden JA, Khayter C, et al. High-frequency off- target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013;31(9):822-826.
  12. Nakade S, Yamamoto T, Sakuma T. Cas9, Cpf1 and C2c1/ 2/3-What's next? Bioengineered. 2017;8(3):265-273.
  13. Kleinstiver BP, Pattanayak V, Prew MS, et al. High-fide- lity CRISPR-Cas9 nucleases with no detectable genome- wide off-target effects. Nature. 2016;529(7587):490-495.
  14. Kleinstiver BP, Prew MS, Tsai SQ, et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature. 2015;523(7561):481-485.
  15. Ran FA, Hsu PD, Lin CY, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome edit- ing specificity. Cell. 2013; 155:479-480.
  16. Ran FA, Cong L, Yan WX, et al. In vivo genome editing using staphylococcus aureus Cas9. Nature. 2015;520(7546):186-191.
  17. Zetsche B, Gootenberg JS, Abudayyeh OO, et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell. 2015;163:759-771.
  18. Scheben A, Wolter F, Batley J, et al. Towards CRISPR/ Cas crops -bringing together genomics and genome editing. New Phytol. 2017;216(3):682-698.
  19. Cong, L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013; 339:819-823.
  20. Abudayyeh OO, Gootenberg JS, Essletzbichler P, et al. RNA targeting with CRISPR-cas13. Nature. 2017;550 (7675):280.
  21. Cox DBT, Gootenberg JS, Abudayyeh OO, et al. RNA editing with CRISPR-Cas13. Science. 2017;358 (6366):1019-1027.
  22. O'Connell MR, Oakes BL, Sternberg SH, et al. Programmable RNA recognition and cleavage by CRISPR/Cas9. Nature. 2014;516(7530):263-266.
  23. Nelles DA, Fang MY, O'Connell MR, et al. Programmable RNA tracking in live cells with CRISPR/Cas9. Cell. 2016;165(2):488-496.
  24. Lundh M, Pluciñska K, Isidor MS, et al. Bidirectional manipulation of gene expression in adipocytes using CRISPRa and siRNA. Mol Metab. 2017;6:1313-1320.
  25. Lo A, Qi L. Genetic and epigenetic control of gene expression by CRISPR-cas systems. F1000. 2017;6: Faculty Rev-747.
  26. Gilbert LA, Horlbeck MA, Adamson B, et al. Genome- scale CRISPR-mediated control of gene repression and activation. Cell. 2014;159:647-661.
  27. Qi LS, Larson MH, Gilbert LA, et al. Repurposing CRISPR as an RNA-guided platform for sequence-speci- fic control of gene expression. Cell. 2013;152:1173-1183.
  28. Jost M, Chen Y, Gilbert LA, et al. Combined CRISPRi/ a-based chemical genetic screens reveal that rigosertib is a microtubule-destabilizing agent. Mol Cel. 2017;68 (1):210-223.
  29. Kampmann M. CRISPRi and CRISPRa screens in mammalian cells for precision biology and medicine. ACS Chem Biol. 2017; 13:406-416.
  30. Chen B, Gilbert LA, Cimini BA, et al. Dynamic ima- ging of genomic loci in living human cells by an opti- mized CRISPR/Cas system. Cell. 2013;155:1479-1491.
  31. Ma H, Naseri A, Reyes-Gutierrez P, et al. Multicolor CRISPR labeling of chromosomal loci in human cells. Proc Natl Acad Sci USA. 2015;112:3002-3007.
  32. Klug A. The discovery of zinc fingers and their appli- cations in gene regulation and genome manipulation. Annu Rev Biochem. 2010;79:213-231.
  33. Li T, Huang S, Jiang WZ, et al. TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain. Nucl Acids Res. 2011;39(1):359-372.
  34. Brinegar K, Yetisen A, Choi S, et al. The commercializa- tion of genome-editing technologies. Crit Rev Biotechnol. 2017;37(7):924-932.
  35. Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bac- terial immunity. Science. 2012;337(6096):816-821.
  36. Ledford H. How the US CRISPR patent probe will play out. Nat News [Internet]. 2016 Mar 10;531(7593):149. [cited 2017 Dec 29]. Available from:: http://www.nat ure.com.ezproxy.library.uwa.edu.au/news/how-the-us- crispr-patent-probe-will-play-out-1.19519
  37. Cohen J. Ding, ding, ding! CRISPR patent fight enters next round [Internet]. 2017 Jul 26, Am 9: 00. [cited 2017 Dec 29]. Available from: http://www.sciencemag. org.ezproxy.library.uwa.edu.au/news/2017/07/ding- ding-ding-crispr-patent-fight-enters-next-round
  38. CRISPR COMMERCIALIZATION RISK | REGENHEALTHSOLUTIONS [Internet]. [cited 2017 Dec 29]. Available from: http://www.regenhealthsolu tions.info/4/crispr_commercialization_risk_780838.html
  39. Wolter F, Puchta H. Knocking out consumer concerns and regulator's rules: efficient use of CRISPR/Cas ribo- nucleoprotein complexes for genome editing in cereals. Genome Biol. 2017;18:43.